Article

Diagnostics firm finalizes Matritech acquisition

Inverness Medical Innovations, Inc. has finalized its acquisition of Matritech, Inc., the manufacturer of the NMP22 BladderChek Test.

Inverness Medical Innovations, Inc. has finalized its acquisition of Matritech, Inc., the manufacturer of the NMP22 BladderChek Test.

The BladderChek is a point-of-care test cleared by the FDA for both the diagnosis and monitoring of bladder cancer. Inverness is an international developer of point-of-care diagnostics related to infectious disease, cardiology, oncology, drugs of abuse, and women’s health.

“Matritech’s expertise in the development of protein-based diagnostic products for the early detection of cancer is a terrific addition to the Inverness portfolio of products and capabilities, said Ron Zwanziger, CEO of Inverness.

Related Videos
Man talking with doctor, who is taking notes on a clipboard | Image Credit: © DragonImages - stock.adobe.com
Chad Tang, MD: Considerations for SBRT in metastatic RCC
Ravi Munver, MD, answers a question during a Zoom video interview
Interpreting ART toxicity and tolerability for bladder cancer, with Vedang Murthy, MD
1 KOL is featured in this series.
Related Content
Nivolumab plus SOC associated with improved FFBR in GG5 prostate cancer
October 11th 2024

Nivolumab plus SOC associated with improved FFBR in GG5 prostate cancer

Hannah Clarke
“Nivolumab, combined with standard of care trimodality therapy, appears to be promising for the treatment of grade group 5 prostate cancer," says John Michael Bryant, MD.
Key updates from the AUA/ASRM male infertility guideline amendment
September 23rd 2024

Key updates from the AUA/ASRM male infertility guideline amendment

Urology Times staff
In this episode, Robert E. Brannigan, MD, and Juan J. Andino, MD, MBA, discuss the recent amendment to the AUA/ASRM guideline on male infertility.
3d rendered illustration - bladder cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
October 11th 2024

Biomarker may predict MIBC status following neoadjuvant chemo

Elizabeth R. Plimack, MD, MS, FASCO
"The biomarker is better at predicting presence of disease than absence, and the reason that that's important is that's how we can think about the biomarker aiding in careful clinical assessment of patients," says Elizabeth R. Plimack, MD, MS, FASCO.
Speaking of Urology: Dr. Winter on the use of vaginal estrogen
July 24th 2024

Speaking of Urology: Dr. Winter on the use of vaginal estrogen

Urology Times staff
In this episode of Speaking of Urology®, Ashley G. Winter, MD, discusses the use of vaginal estrogen.
Human kidney stones | Image Credit: © freshidea - stock.adobe.com
October 10th 2024

How to code for cystoscopy with litholapaxy of more than 40 bladder calculi

Jonathan Rubenstein, MD Mark Painter
"If the documentation supported the use of modifier –22, it should be appended," write Jonathan Rubenstein, MD, and Mark Painter.
Bridget Koontz, MD: 18F-flotufolastat demonstrates high detection rate in low PSA setting
October 10th 2024

Bridget Koontz, MD: 18F-flotufolastat demonstrates high detection rate in low PSA setting

Urology Times staff
"We found that as soon as we got to the range of biochemical recurrence-defined PSA—0.2 ng/mL and up—the detection rate was very high," says Bridget Koontz, MD, FASTRO.
© 2024 MJH Life Sciences

All rights reserved.